Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo

British Journal of Cancer

Volumn 97, Issue 6, 2007, Pages 761-768

  Mellor, P ^a   Harvey, J R ^a   Murphy, K J ^b   Pye, D ^b   O'Boyle, G ^a   Lennard, T W J ^a   Kirby, J A ^a   Ali, S ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Breast cancer; CXCL12; CXCR4; Glycosaminoglycan; Metastasis

Indexed keywords

CARBOHYDRATE DERIVATIVE; DEXTRAN 40; HEPARAN SULFATE; HEPARIN; HEPARIN DODECASACCHARIDE DERIVATIVE; IODINE 125; OLIGOSACCHARIDE; STROMAL CELL DERIVED FACTOR 1; TINZAPARIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; DRUG MECHANISM; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; CHEMOKINES, CXC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MICE; MICE, SCID; OLIGOSACCHARIDES; POLYMERS; RADIOLIGAND ASSAY; RECEPTORS, CXCR4;

EID: 34548585134     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603928     Document Type: Article

References (49)

1. Ali S, Palmer AC, Banerjee B, Fritchley SJ, Kirby JA (2000) Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. J Biol Chem 275: 11721-11727
2. Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA (2005) A nonglycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol 175: 1257-1266
3. Altundag K, Altundag O, Atik MA (2005) Heparin and CXCL12 dimerization. J Clin Oncol 23: 7248
4. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, Virelizier JL, Delepierre M, Baleux F, Lortat-Jacob H, Arenzana-Seisdedos F (1999) Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem 274: 23916-23925
5. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62: 1093-1102
6. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760-35766
7. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG (1997) Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75: 429-439
8. Borsig L (2004) Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol Sci 19: 16-21
9. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213
10. Castelli R, Porro F, Tarsia P (2004) The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9: 205-213
11. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT (2006) CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol 154: 910-918
12. Douglas MS, Ali S, Rix DA, Zhang JG, Kirby JA (1997) Endothelial production of MCP-1: modulation by heparin and consequences for mononuclear cell activation. Immunology 92: 512-518
13. Dowsland MH, Harvey JR, Lennard TW, Kirby JA, Ali S (2003) Chemokines and breast cancer: a gateway to revolutionary targeted cancer treatments? Curr Med Chem 10: 579-592
14. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173
15. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23: 157-167
16. Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC (2005) Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 11: 8172-8179
17. Hecht I, Hershkoviz R, Shivtiel S, Lapidot T, Cohen IR, Lider O, Cahalon L (2004) Heparin-disaccharide affects T cells: inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J Leukoc Biol 75: 1139-1146
18. Herault JP, Bernat A, Roye F, Michaux C, Schaeffer P, Bono F, Petitou M, Herbert JM (2002) Pharmacokinetics of new synthetic heparin mimetics. Thromb Haemost 87: 985-989
19. Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood 79: 1-17
20. Hirsh J (1998) Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 98: 1575-1582
21. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells TN (1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36: 13570-13578
22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
23. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ (1993) Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 268: 4675-4683
24. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A (1998) Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 101: 877-889
25. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ (2004) CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35: 233-245
26. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38: 12959-12968
27. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218: 725-732
28. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65: 967-971
29. Lindahl U, Backstrom G, Hook M, Thunberg L, Fransson LA, Linker A (1979) Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 76: 3198-3202
30. Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25(Suppl 3): 5-16
31. Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238: 30-41
32. Moore MA (2001) The role of chemoattraction in cancer metastases. Bioessays 23: 674-676
33. Moser B, Wolf M, Walz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25: 75-84
34. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56
35. Murphy PM (2001) Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345: 833-835
36. Nader HB, Pinhal MA, Bau EC, Castro RA, Medeiros GF, Chavante SF, Leite EL, Trindade ES, Shinjo SK, Rocha HA, Tersariol IL, Mendes A, Dietrich CP (2001) Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells. Braz J Med Biol Res 34: 699-709
37. Norrby K, Ostergaard P (1996) Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 16: 8-15
38. Perrimon N, Bernfield M (2000) Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404: 725-728
39. Proudfoot AE (2006) The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 34: 422-426
40. Sadir R, Baleux F, Grosdidier A, Imberty A, Lortat-Jacob H (2001) Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem 276: 8288-8296
41. Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G (1994) Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem Biophys Res Commun 203: 1339-1347
42. Tyrrell DJ, Ishihara M, Rao N, Horne A, Kiefer MC, Stauber GB, Lam LH, Stack RJ (1993) Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 268: 4684-4689
43. Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF (2005) The monomerdimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 14: 1071-1081
44. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, Ishai-Michaeli R, Peretz T (1994) Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14: 290-302
45. Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA (1997) Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev 16: 5-27
46. Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80: 1529-1537
47. Wu CL (2001) Regional anesthesia and anticoagulation. J Clin Anesth 13: 49-58
48. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127
49. Zlotnik A (2006) Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol 13: 191-199